Internal Medicine, Cardiovascular Disease · Moorestown, NJ
NPI
1487621090
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
728 Marne Hwy Ste 200a
Moorestown, NJ, 08057
Phone (856) 291-8855
Groups this clinician bills Medicare through
Medicare paid, 2024
$142K
2,439 services
Medicare patients, 2024
690
Average age 78
Drug cost, 2024
$1.5M
7,409 prescriptions
Company payments, 2025
$420
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vincent Spagnuolo was code 99214 (office e&m - established), 999 times for 608 patients. In total Vincent Spagnuolo billed 2,439 services in 30 codes, and Medicare paid $142K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-04-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 999 | 608 | $99.10 | $99K |
| 93000 Electrocardiogram | Office | 961 | 624 | $11.48 | $11K |
| 93306 Echocardiography (TTE/TEE) | Office | 164 | 154 | $88.23 | $14K |
| 93280 External Electrocardiographic Monitoring | Office | 41 | 26 | $66.93 | $2,744 |
| 99204 Office E&M - New | Office | 41 | 41 | $133.58 | $5,477 |
| 85610 Clinical Chemistry | Office | 30 | 20 | $4.20 | $126 |
| 93224 Electrocardiogram | Office | 26 | 26 | $58.03 | $1,509 |
| 93356 Echocardiography (TTE/TEE) | Office | 20 | 19 | $29.35 | $587 |
| 93228 Electrocardiogram | Office | 16 | 15 | $22.13 | $354 |
| 93248 Electrocardiogram | Office | 14 | 13 | $22.40 | $314 |
By year: 2022 $227K for 3,774 services; 2023 $177K for 2,902 services; 2024 $142K for 2,439 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 30 | 20 | $4.20 | $126 |
Medicare prescription drug claims, 2024
In 2024, the drug Vincent Spagnuolo prescribed most often to Medicare patients was Atorvastatin Calcium, with 688 prescriptions and refills. In total Vincent Spagnuolo wrote 7,409 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 688 | 1,887 | 193 | $8,174 |
| Eliquis Apixaban | 589 | 1,241 | 145 | $707K |
| Amlodipine Besylate Generic | 477 | 1,348 | 143 | $3,748 |
| Rosuvastatin Calcium Generic | 476 | 1,308 | 142 | $6,536 |
| Metoprolol Succinate Generic | 469 | 1,246 | 136 | $7,401 |
| Metoprolol Tartrate Generic | 443 | 1,209 | 135 | $3,453 |
| Carvedilol Generic | 374 | 1,007 | 106 | $4,207 |
| Losartan Potassium Generic | 341 | 906 | 97 | $3,095 |
| Furosemide Generic | 241 | 577 | 78 | $1,199 |
| Ezetimibe Generic | 205 | 599 | 68 | $5,746 |
| Lisinopril Generic | 205 | 591 | 63 | $1,297 |
| Hydrochlorothiazide Generic | 202 | 595 | 67 | $996 |
| Xarelto Rivaroxaban | 191 | 428 | 48 | $231K |
| Spironolactone Generic | 162 | 434 | 47 | $1,294 |
| Clopidogrel Clopidogrel Bisulfate | 154 | 444 | 54 | $2,447 |
Brand drugs: 1,297 claims; generic drugs: 6,112 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vincent Spagnuolo $420 ($420 in general payments such as food, travel and fees) from 9 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $144.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 18 | $144 |
| Amgen Inc. AMGN | 4 | $66.39 |
| Boston Scientific Corporation BSX | 2 | $62.57 |
| Kestra Medical Technology Services, Inc. | 2 | $42.78 |
| Impulse Dynamics (USA) Inc. | 1 | $32.92 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $18.98 |
| Ionis Pharmaceuticals, Inc. IONS | 1 | $18.87 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $16.87 |
| Merck Sharp & Dohme LLC MRK | 1 | $16.27 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.